文献速递肺栓塞与肺血管病

ST2 是儿童肺动脉高压严重程度与临床恶化的生物标志物

ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.
PubMed 文献 · Chest · 2021-02-18

在儿童肺动脉高压的两个队列中评估可溶性 ST2 与肺血流动力学、功能指标及临床恶化的关联。校正分析显示 ST2 与更短 6 分钟步行距离、更高肺血管阻力指数和更高平均肺动脉压相关,且加入 ST2 可显著改善 REVEAL 风险评分对临床恶化的预测。体外实验提示 ST2 主要由肺动脉内皮细胞而非平滑肌细胞产生和分泌。

要点

  • ST2 与儿童肺动脉高压的肺血流动力学和功能指标恶化相关。
  • 在 REVEAL 评分基础上加入 ST2 可改善临床恶化预测。
  • ST2 主要由肺动脉内皮细胞分泌,提示其肺血管特异性。

核心结论

  • 在两个儿童肺动脉高压队列中,ST2 升高与不良肺血流动力学、功能指标及临床恶化相关,并显著改善临床恶化预测。

研究设计与样本

  • 研究纳入两个年龄小于 21 岁的儿童队列:PAHB 横断面队列 N=182,Children's Hospital of Colorado 纵向队列 N=61,检测 ST2 与 NT-proBNP。
  • 采用校正线性回归分析 ST2 与临床变量的关联,并比较含或不含 ST2 的 REVEAL 评分对临床恶化的预测。
  • 体外检测肺动脉内皮细胞和平滑肌细胞的 ST2 表达与分泌。

主要发现

  • PAHB 队列校正年龄和性别后,ST2 与更短 6 分钟步行距离(P = .03)和更高肺血管阻力指数(P = .02)显著相关。
  • Colorado 队列校正纵向回归中,ST2 与更高肺血管阻力指数(P < .001)、更短 6 分钟步行距离(P = .01)和更高平均肺动脉压(P < .001)显著相关。
  • REVEAL 风险评分计算器 2.0 可预测 PAHB 临床恶化(风险比 1.88),加入 ST2 后模型显著改善(风险比 2.05)。
  • 细胞培养中 ST2 主要由内皮细胞而非平滑肌细胞产生和分泌(P < .0001)。

关键数值与推荐

  • PAHB 队列:ST2 与 6 分钟步行距离(P = .03)和肺血管阻力指数(P = .02)显著相关。
  • Colorado 队列:ST2 与肺血管阻力指数(P < .001)、6 分钟步行距离(P = .01)和平均肺动脉压(P < .001)显著相关。
  • PAHB 队列中 REVEAL 评分预测临床恶化风险比 1.88,加入 ST2 后风险比 2.05。
  • 内皮细胞与平滑肌细胞 ST2 分泌差异 P < .0001。

临床怎么用

  • ST2 可作为儿童肺动脉高压肺血管特异性生物标志物,辅助评估病情严重程度和临床恶化风险。
  • 在 REVEAL 评分基础上联合 ST2 可能改善儿童肺动脉高压的风险分层。

局限性

  • 研究为两个队列的观察性分析,样本量分别为 182 和 61,结论需更大规模验证。
  • 体外细胞实验不能完全反映体内 ST2 的生物学功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric pulmonary hypertension is a severe disease defined by sustained elevation of pulmonary artery pressures and pulmonary vascular resistance (PVR). Noninvasive diagnostic and prognostic markers that are more pulmonary vascular specific have been elusive because of disease heterogeneity and patient growth. RESEARCH QUESTION: Is soluble suppressor of tumorigenicity (ST2) associated with pulmonary hemodynamic and functional changes in pediatric pulmonary hypertension? Does ST2 improve mortality risk models in pediatric pulmonary hypertension? STUDY DESIGN AND METHODS: Two pediatric cohorts (age < 21 years) were assayed for ST2 and N-terminal prohormone B-natriuretic peptide: a cross-sectional cohort from the National Heart Lung and Blood Institute-funded National Biological Sample and Data Repository for PAH (PAHB) (N = 182), and a second longitudinal cohort from Children's Hospital of Colorado (N = 61). Adjusted linear regression was used for association with clinical variables. Clinical mortality models (the Registry to Evaluate Early and Long-Term PAH Disease Management [REVEAL] score) with and without ST2 were used to predict worsening outcomes and compared. Pulmonary artery endothelial and smooth muscle cell ST2 expression and secretion were assayed in vitro. RESULTS: In an adjusted (age and sex) analysis in the PAHB, ST2 was significantly associated with shorter 6-min walk distance (P = .03) and increased PVR index (P = .02). In adjusted longitudinal regression in the Children's Hospital of Colorado cohort, ST2 was significantly associated with higher PVR index (P < .001), shorter 6-min walk distance (P = .01), and higher mean pulmonary artery pressure (P < .001). Although the REVEAL Risk Score Calculator 2.0 was predictive of clinical worsening in the PAHB (hazard ratio, 1.88), addition of ST2 significantly improved the model (hazard ratio, 2.05). In cell culture, ST2 was produced and secreted predominately by endothelial cells as opposed to smooth muscle cells (P < .0001). INTERPRETATION: In two pediatric PAH cohorts, elevated ST2 was associated with unfavorable pulmonary hemodynamics and functional measures, clinical worsening, and significantly improved prediction of clinical worsening. Pulmonary artery endothelial cellular expression of ST2 suggests that ST2 is a more pulmonary vascular-specific marker for pulmonary hypertension.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Griffiths M, Yang J, Simpson CE, et al. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest. 2021. PMID: 33609516. doi:10.1016/j.chest.2021.01.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。